Regulatory uncertainty brings risk and opportunity to pharma in 2025, says Jeff Lemay

CCO Jeff Lemay reflects on his time at Jazz Pharmaceuticals and asseses the road ahead for compliance and legal teams in the pharma sector.

New market and policy initiatives in 2025 create a truly challenging healthcare environment, but they also present businesses and stakeholders with the opportunity to expand into some new areas, such as new technology leveraging artificial intelligence (AI).

Functions are rarely siloed any longer, as teams must collaborate to navigate ever-changing supply

Free Trial

Register for free to keep reading.

To continue reading this article and unlock full access to GRIP, register now. You’ll enjoy free access to all content until our subscription service launches in early 2026.

  • Unlimited access to industry insights
  • Stay on top of key rules and regulatory changes with our Rules Navigator
  • Ad-free experience with no distractions
  • Regular podcasts from trusted external experts
  • Fresh compliance and regulatory content every day
Register for free Already a member? Sign in